PDCD1LG2 and fibrosarcoma: We have here tested the therapeutic efficacy of monoclonal Abs targeting PDL1 and PDL2 molecules in combination with cyclophosphamide (CTX), an alkylating agent endowed with well-characterized immunomodulatory effects [15,16,17], in mouse models of lymphoma (EG.7-OVA) and fibrosarcoma (MCA205) with distinct intrinsic immunogenic potential.